- Home
- LNG vs ALNY Comparison
LNG vs ALNY Comparison
Compare LNG & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LNG
- ALNY
- Stock Information
- Founded
- LNG 1983
- ALNY 2002
- Country
- LNG United States
- ALNY United States
- Employees
- LNG N/A
- ALNY N/A
- Industry
- LNG Oil/Gas Transmission
- ALNY Biotechnology: Pharmaceutical Preparations
- Sector
- LNG Utilities
- ALNY Health Care
- Exchange
- LNG Nasdaq
- ALNY Nasdaq
- Market Cap
- LNG 40.7B
- ALNY 33.1B
- IPO Year
- LNG 1997
- ALNY 2004
- Fundamental
- Price
- LNG $210.49
- ALNY $243.25
- Analyst Decision
- LNG Strong Buy
- ALNY Buy
- Analyst Count
- LNG 10
- ALNY 23
- Target Price
- LNG $223.20
- ALNY $298.59
- AVG Volume (30 Days)
- LNG 1.5M
- ALNY 633.0K
- Earning Date
- LNG 02-20-2025
- ALNY 02-13-2025
- Dividend Yield
- LNG 0.95%
- ALNY N/A
- EPS Growth
- LNG N/A
- ALNY N/A
- EPS
- LNG 15.70
- ALNY N/A
- Revenue
- LNG $15,579,000,000.00
- ALNY $2,094,795,000.00
- Revenue This Year
- LNG N/A
- ALNY $25.09
- Revenue Next Year
- LNG $16.21
- ALNY $16.75
- P/E Ratio
- LNG $13.40
- ALNY N/A
- Revenue Growth
- LNG N/A
- ALNY 21.54
- 52 Week Low
- LNG $152.31
- ALNY $141.98
- 52 Week High
- LNG $228.10
- ALNY $304.39
- Technical
- Relative Strength Index (RSI)
- LNG 48.12
- ALNY 42.07
- Support Level
- LNG $203.40
- ALNY $233.41
- Resistance Level
- LNG $210.23
- ALNY $247.21
- Average True Range (ATR)
- LNG 4.42
- ALNY 7.84
- MACD
- LNG -1.74
- ALNY 0.04
- Stochastic Oscillator
- LNG 28.70
- ALNY 39.82
About LNG Cheniere Energy Inc.
Cheniere Energy owns and operates the Sabine Pass liquefied natural gas terminal via its stake in Cheniere Partners. It also owns the Corpus Christi LNG terminals as well as Cheniere Marketing, which markets LNG using Cheniere's gas volumes.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. It also has several clinical programs across various therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Upfront fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.